ORLANDO, Fla., April 5, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the development of 2 new antibodies produced by the Company's proprietary Dock-and-Lock (DNL) technology for the potential treatment of mantle cell lymphoma (MCL) and other B-cell lymphomas.
